(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Renal Cell Carcinoma
This is a randomized, controlled, open-label multi-center trial to evaluate the clinical benefit of BAY 43-9006 compared to a standard therapy with IFN in patients with unresectable and / or metastatic renal cell cancer who have received no prior systemic therapy. Patients receiving 400 mg bid sorafenib will receive a dose escalation to 600 mg bid following progression. Participants must have a life expectancy of at least 12 weeks, have unresectable and/or metastatic, measurable predominantly clear cell RCC, and have undergone prior (at the time of primary diagnosis) complete surgical excision of primary RCC tumor. Research site located in Dallas, Texas.
More Information
Please see http://www.centerwatch.com/patient/studies/cat363.html.
-----
Surgery
North Shore University Hospital is conducting a study in women with anterior vaginal wall prolapse who require surgery. This study will use a new surgical procedure to allow repair of this problem with a synthetic mesh device. You may participate in this study if you have been diagnosed with clinically significant anterior vaginal wall prolapse requiring surgical repair, and your physician believes you to be a good candidate. Research site located in Great Neck, NY.
More Information
Please see http://www.centerwatch.com/patient/studies/cat614.html.
-----
Generalized Anxiety Disorder
The Mood and Anxiety Disorders Program of Emory University is conducting a research study of an investigational medication for people with generalized anxiety disorder. Participants must be 18 to 65 years of age and in stable medical condition. A psychiatric evaluation, a physical exam, laboratory test and study medication are provided at no cost. Participation could last up to eight weeks. Research site located in Atlanta, Ga.
More Information
Please see http://www.centerwatch.com/patient/studies/cat503.html.
-----
Copyright 2005 CenterWatch. All rights reserved.
